Switch theme
Sign up to access all valuation multiples
Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods as well as provides distribution services relating to such products. The company's product portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purposes and sale of goods manufactured by third parties; and OEM.
1982
5.5K+
LTM Revenue $445M
LTM EBITDA $94.8M
$607M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mega Lifesciences has a last 12-month revenue of $445M and a last 12-month EBITDA of $94.8M.
In the most recent fiscal year, Mega Lifesciences achieved revenue of $451M and an EBITDA of $78.6M.
Mega Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mega Lifesciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $461M | $451M | XXX | XXX | XXX |
| Gross Profit | $207M | $209M | XXX | XXX | XXX |
| Gross Margin | 45% | 46% | XXX | XXX | XXX |
| EBITDA | $75.8M | $78.6M | XXX | XXX | XXX |
| EBITDA Margin | 16% | 17% | XXX | XXX | XXX |
| Net Profit | $65.9M | $58.6M | XXX | XXX | XXX |
| Net Margin | 14% | 13% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Mega Lifesciences's stock price is THB 28 (or $1).
Mega Lifesciences has current market cap of THB 24.0B (or $705M), and EV of THB 20.7B (or $607M).
See Mega Lifesciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $607M | $705M | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Mega Lifesciences has market cap of $705M and EV of $607M.
Mega Lifesciences's trades at 1.4x LTM EV/Revenue multiple, and 6.4x LTM EBITDA.
Analysts estimate Mega Lifesciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Mega Lifesciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $607M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 7.7x | XXX | XXX | XXX |
| P/E | 11.9x | XXX | XXX | XXX |
| P/E/Growth | 1.2x | XXX | XXX | XXX |
| EV/FCF | 9.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMega Lifesciences's NTM/LTM revenue growth is -2%
Mega Lifesciences's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $23K for the same period.
Over next 12 months, Mega Lifesciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Mega Lifesciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Mega Lifesciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 16% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $23K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 29% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mega Lifesciences acquired XXX companies to date.
Last acquisition by Mega Lifesciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Mega Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Mega Lifesciences founded? | Mega Lifesciences was founded in 1982. |
| Where is Mega Lifesciences headquartered? | Mega Lifesciences is headquartered in Thailand. |
| How many employees does Mega Lifesciences have? | As of today, Mega Lifesciences has 5.5K+ employees. |
| Who is the CEO of Mega Lifesciences? | Mega Lifesciences's CEO is Mr. Vivek Dhawan. |
| Is Mega Lifesciences publicy listed? | Yes, Mega Lifesciences is a public company listed on BKK. |
| What is the stock symbol of Mega Lifesciences? | Mega Lifesciences trades under MEGA ticker. |
| When did Mega Lifesciences go public? | Mega Lifesciences went public in 2013. |
| Who are competitors of Mega Lifesciences? | Similar companies to Mega Lifesciences include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Mega Lifesciences? | Mega Lifesciences's current market cap is $705M |
| What is the current revenue of Mega Lifesciences? | Mega Lifesciences's last 12-month revenue is $445M. |
| What is the current EBITDA of Mega Lifesciences? | Mega Lifesciences's last 12-month EBITDA is $94.8M. |
| What is the current EV/Revenue multiple of Mega Lifesciences? | Current revenue multiple of Mega Lifesciences is 1.4x. |
| What is the current EV/EBITDA multiple of Mega Lifesciences? | Current EBITDA multiple of Mega Lifesciences is 6.4x. |
| What is the current revenue growth of Mega Lifesciences? | Mega Lifesciences revenue growth between 2023 and 2024 was -2%. |
| Is Mega Lifesciences profitable? | Yes, Mega Lifesciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
